X4 PharmaceuticalsXFOR
About: X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
Employees: 127
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
232% more call options, than puts
Call options by funds: $349K | Put options by funds: $105K
89% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 19
1% more funds holding
Funds holding: 98 [Q1] → 99 (+1) [Q2]
6% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 17
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
1.71% less ownership
Funds ownership: 62.17% [Q1] → 60.46% (-1.71%) [Q2]
59% less capital invested
Capital invested by funds: $145M [Q1] → $58.9M (-$86.2M) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for XFOR.
